Literature DB >> 19759158

Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions.

Linda L Dunn1, Mary Jane McWilliams, Kalyan Das, Eddy Arnold, Stephen H Hughes.   

Abstract

Although human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) has been extensively studied, there are still significant questions about the effects of mutations on the maturation and stability of RT. We show here that a significant fraction (>80%) of the single point mutations we generated in the thumb subdomain of HIV-1 (RT) affect the stability of RT in virions. Fragments of the unstable mutant RTs can be detected in Western blots of virion proteins; however, the degree of degradation varies. The titers of the mutants whose virions contain degraded RTs are reduced. Some, but not all, of the unstable RT thumb subdomain mutants we analyzed have a temperature-sensitive phenotype. A preliminary survey of mutations in other subdomains of RT shows that some of these mutations also destabilize RT. The stability of the RT mutants is enhanced by the addition of a protease inhibitor, suggesting that the viral protease plays an important role in the degradation of the mutant RTs. These results confirm and extend earlier reports of mutations that affect the stability of RT in virions. The data suggest that the stability of a mutant RT in virions could be a major factor in determining the virus titer and, by extension, viral fitness, which could affect whether a mutation in RT is acceptable to the virus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759158      PMCID: PMC2786724          DOI: 10.1128/JVI.00676-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Immunologic and proteolytic analysis of HIV-1 reverse transcriptase structure.

Authors:  A L Ferris; A Hizi; S D Showalter; S Pichuantes; L Babe; C S Craik; S H Hughes
Journal:  Virology       Date:  1990-04       Impact factor: 3.616

4.  Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution.

Authors:  A Jacobo-Molina; A D Clark; R L Williams; R G Nanni; P Clark; A L Ferris; S H Hughes; E Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.

Authors:  Lu Gao; Mark Nils Hanson; Mini Balakrishnan; Paul L Boyer; Bernard P Roques; Stephen H Hughes; Baek Kim; Robert A Bambara
Journal:  J Biol Chem       Date:  2008-01-24       Impact factor: 5.157

6.  Selective degradation of abnormal proteins in mammalian tissue culture cells.

Authors:  M R Capecchi; N E Capecchi; S H Hughes; G M Wahl
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

7.  Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Authors:  S G Sarafianos; K Das; C Tantillo; A D Clark; J Ding; J M Whitcomb; P L Boyer; S H Hughes; E Arnold
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

8.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations.

Authors:  Kalyan Das; Joseph D Bauman; Arthur D Clark; Yulia V Frenkel; Paul J Lewi; Aaron J Shatkin; Stephen H Hughes; Eddy Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

9.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

10.  Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.

Authors:  Wei Huang; Andrea Gamarnik; Kay Limoli; Christos J Petropoulos; Jeannette M Whitcomb
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  13 in total

1.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  HIV-1 reverse transcription.

Authors:  Wei-Shau Hu; Stephen H Hughes
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 4.  Reverse Transcription of Retroviruses and LTR Retrotransposons.

Authors:  Stephen H Hughes
Journal:  Microbiol Spectr       Date:  2015-04

5.  Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H.

Authors:  Suhman Chung; Michaela Wendeler; Jason W Rausch; Greg Beilhartz; Matthias Gotte; Barry R O'Keefe; Alun Bermingham; John A Beutler; Shixin Liu; Xiaowei Zhuang; Stuart F J Le Grice
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.

Authors:  Gilberto Betancor; Maria C Puertas; María Nevot; César Garriga; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

7.  Induced maturation of human immunodeficiency virus.

Authors:  Simone Mattei; Maria Anders; Jan Konvalinka; Hans-Georg Kräusslich; John A G Briggs; Barbara Müller
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

8.  Mutations in HIV-1 reverse transcriptase cause misfolding and miscleavage by the viral protease.

Authors:  Linda L Dunn; Paul L Boyer; Patrick K Clark; Stephen H Hughes
Journal:  Virology       Date:  2013-07-11       Impact factor: 3.616

9.  Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design.

Authors:  Doty B A Ojwach; Paradise Madlala; Michelle Gordon; Thumbi Ndung'u; Jaclyn K Mann
Journal:  Virology       Date:  2020-12-10       Impact factor: 3.616

10.  Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy.

Authors:  Gilberto Betancor; César Garriga; Maria C Puertas; María Nevot; Lourdes Anta; José L Blanco; M Jesús Pérez-Elías; Carmen de Mendoza; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias; José Antonio Iribarren; Estrella Caballero; Esteban Ribera; Josep Maria Llibre; Bonaventura Clotet; Angels Jaén; David Dalmau; José María Gatel; Joaquín Peraire; Francesc Vidal; Carmen Vidal; Melchor Riera; Juan Córdoba; José López Aldeguer; María José Galindo; Félix Gutiérrez; Marta Álvarez; Federico García; Pilar Pérez-Romero; Pompeyo Viciana; Manuel Leal; José Carlos Palomares; Juan Antonio Pineda; Isabel Viciana; Jesús Santos; Patricia Rodríguez; Juan Luis Gómez Sirvent; Carolina Gutiérrez; Santiago Moreno; Mayte Pérez-Olmeda; José Alcamí; Carmen Rodríguez; Jorge del Romero; Angelina Cañizares; José Pedreira; Celia Miralles; Antonio Ocampo; Luis Morano; Antonio Aguilera; Carolina Garrido; Gustavo Manuzza; Eva Poveda; Vicente Soriano
Journal:  Retrovirology       Date:  2012-08-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.